Pantogam, pills 250mg, 50pcs

Composition

Active ingredient:

calcium hopanthenate (Pantogam®) 250 and 500 mg;

Auxiliary substances:

methylcellulose,

calcium stearate,

magnesium hydroxycarbonate,

talc

Pharmacological action

The spectrum of action of Pantogam® is associated with the presence of gamma-aminobutyric acid (GABA) in its structure. The mechanism of action is due to the direct effect of the drug on the GABAB-receptor-channel complex.

It has a nootropic and anticonvulsant effect. Increases the brain’s resistance to hypoxia and toxic substances, stimulates anabolic processes in neurons, combines a moderate sedative effect with a mild stimulating effect, reduces motor excitability, activates mental and physical performance.

Improves GABA metabolism during chronic alcohol intoxication and after ethanol withdrawal.

It is able to inhibit acetylation reactions involved in the mechanisms of inactivation of procaine (novocaine) and sulfonamides, thereby prolonging the action of the latter. Causes inhibition of pathologically elevated cystic reflex and detrusor tone.

Pharmacokinetics

Pantogam® rapidly absorbed from the gastrointestinal tract, passes through the BBB, the highest concentrations are created in the liver, kidneys, stomach wall and skin. It is not metabolized and is excreted unchanged within 48 hours: 67.5% of the dose taken is excreted in the urine,28.5% – in the feces.

Indications

• cognitive disorders in organic brain lesions (including the consequences of neuroinfections and TBI) and neurotic disorders;
• schizophrenia with cerebral organic insufficiency;
• cerebrovascular insufficiency caused by atherosclerotic changes in vessels of the brain;
• extrapyramidal disorders (myoclonus epilepsy, Huntington’s chorea, hepatolenticular degeneration, Parkinson’s disease, etc. );
• treatment and prevention of extrapyramidal syndrome (hyperkinetic and akinetic) caused by neuroleptics;
• epilepsy with slowness of mental processes in complex therapy with anticonvulsants;
• psycho-emotional overload,
• reduced mental and physical performance, to improve concentration and memory;
• neurogenic disorders of urination (pollakiuria, urgency imperative, imperative urinary incontinence, enuresis).
• in children with perinatal encephalopathy;
• mental retardation of varying severity in children;
• developmental delay (mental, speech, motor or a combination of them) in children;
• various forms of cerebral palsy;
• hyperkinetic disorders (attention deficit hyperactivity disorder) in children;
• neurosis-like conditions (with stuttering, mainly in clonic form, tics) in children.

Contraindications

• hypersensitivity;
• acute severe kidney diseases;
• pregnancy (I trimester — syrup);
• pregnancy (tablets);
• phenylketonuria (syrup containing aspartame)
• breast-feeding period (tablets).
• children under 3 years of age (tablets).

Side effects

Allergic reactions:  rhinitis, conjunctivitis, and skin rashes are possible.

Other services:  possible sleep disturbances or drowsiness, tinnitus (these symptoms are usually short-lived and do not require discontinuation of the drug).

Interaction

Prolongs the action of barbiturates, enhances the effect of anticonvulsants, prevents side effects of phenobarbital, carbamazepine, neuroleptics.

Potentiates the action of local anesthetics (procaine).

The effect of Pantogam® is enhanced in combination with glycine, ethidronic acid (xydiphone).

How to take, course of use and dosage

Adults: single dose-0.25-1 g, daily-1.5-3 g; children: single dose-0.25-0.5 g, daily-0.75-3 g. The course of treatment is 1-4 months, in some cases-up to 6 months. After 3-6 months, it is possible to conduct a second course of treatment.

For epilepsy in combination with anticonvulsants-0.75-1 g / day. The course of treatment is up to 1 year or more.

In case of extrapyramidal neuroleptic syndrome in combination with the current therapy, the daily dose is up to 3 g, treatment for several months.

Extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system (combined treatment) — 0.5-3 g/day. The course of treatment is up to 4 months or more.

With the consequences of neuroinfections and TBI — 0.25 g 3-4 times a day.

To restore performance under increased loads and asthenic conditions — 0.25 g 3 times a day.

For the treatment of extrapyramidal syndrome caused by taking neuroleptics, adults-0.5-1 g 3 times a day; children-0.25-0.5 g 3-4 times a day. The course of treatment is 1-3 months.

When ticks occur:  children — 0.25-0.5 g 3-6 times a day, for 1-4 months.

In case of urination disorders:  adults-0.5-1 g 2-3 times a day; children-0.25-0.5 g (daily dose-25-50 mg / kg). The course of treatment is 1-3 months.

Children with various pathologies of the nervous system, depending on age, the drug is recommended in a dose of 1-3 g. The tactics of prescribing the drug: increasing the dose for 7-12 days, taking the maximum dose for 15-40 days and gradually reducing the dose until Pantogam® is discontinued for 7-8 days. The interval between the course of Pantogam®, as for any other nootropic agent, is from 1 to 3 months.

Overdose

Symptoms:  increased symptoms of side effects (sleep disturbance or drowsiness, noise in the head).

Treatment:  use of activated charcoal, gastric lavage, symptomatic therapy.

Special instructions

If allergic reactions develop, the drug should be discontinued.

With long-term treatment, it is not recommended to simultaneously prescribe Pantogam with other nootropic drugs and drugs that stimulate the central nervous system.

Composition

Tablet Form of production

Storage conditions

The drug should be stored in a place protected from light at a temperature of 15° to 20°C.

Shelf life

3 years

Active ingredient

Hopanthenic acid

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as prescribed by a doctor, for children as prescribed by a doctor

Indications

Neurosis, Hyperactivity, Atherosclerosis, Impaired cerebral circulation, Low learning ability, Schizophrenia, Concussion and other traumatic brain injuries, Epilepsy